These findings not only advance our understanding of the underlying molecular mechanisms driving PD but also highlight the therapeutic potential of targeting LRRK2 and the p62-Keap1-Nrf2 pathway for the development of novel neuroprotective strategies (Fig. 11). This evidence concerns the gene KEAP1 and Parkinson disease.